Clinical Trials Browser

Phase 2 × Cholangiocarcinoma × Folfox protocol × Clear all

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06529718 2025-11-17

SEVILLA

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT05712356 2025-06-06

BOLSTER

Phase 2 Active not recruiting

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06946849 2025-04-27

SED-RO-ICC

Phase 2 Not yet recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05535647 2022-09-10

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma